Principal, Roivant Health at Roivant Sciences

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Healthcare, PharmaceuticalsIndustries

Requirements

The ideal candidate is ambitious, entrepreneurial, and comfortable with ambiguity, driven by a passion for building transformational healthcare businesses. They embrace calculated risk-taking as essential to achieving meaningful outcomes for patients, and possess a Bachelor's degree or equivalent experience.

Responsibilities

This role involves full-cycle leadership of one or more incubation categories, from ideation to execution, including leading early-stage ideation by identifying and evaluating potential opportunities based on key success factors, overseeing structured evaluations to de-risk incubations, assessing markets, competitors, product landscapes, and technology, and overseeing the initial company build.

Skills

Market Analysis

Competitive Analysis

Strategic Planning

Due Diligence

Biotechnology

Drug Discovery

Technology Evaluation

Business Incubation

Roivant Sciences

Develops biopharmaceuticals and RNA therapeutics

About Roivant Sciences

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

New York City, New YorkHeadquarters

2014Year Founded

$1,750.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Risks

Integration challenges from Dermavant acquisition may disrupt operations and delay development.

Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.

Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

Differentiation

Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.

The company builds Vants, nimble biotech firms, to enhance drug development efficiency.

Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Upsides

Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.

Strategic partnerships with Bayer and Roche accelerate drug development and market entry.

Increased investment from financial institutions highlights confidence in Roivant's growth potential.

Land your dream remote job 3x faster with AI

Try Jobo Free